Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg
Conditions: Healthy Subjects Interventions: Drug: Empagliflozin-Test product; Drug: Empagliflozin-Reference product Sponsors: Bio-innova Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Ketones, SGLT2, HFrEF
Conditions: Type2diabetes; Heart Failure With Reduced Ejection Fraction Interventions: Drug: Empagliflozin 25 MG Oral Tablet; Drug: Placebo; Drug: Acipimox 250 Mg Oral Capsule Sponsors: The University of Texas Health Science Center at San Antonio; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: CKD-379(Empagliflozin+sitagliptin+metformin) Test drug; Drug: CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug Sponsors: Chong Kun Dang Pharmaceutical Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Conditions: Genetic Polymorphisms; Heart Failure Interventions: Drug: SGLT2 inhibitors (Dapagliflozin and Empagliflozin) Sponsors: October 6 University; University of Florida; National Heart Institute, Egypt; Beni-Suef University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
Treatment of Patients With Diabetic Kidney Disease
Conditions: Diabetic Kidney Disease Interventions: Drug: lisinopril, enalapril; Drug: dapagliflozin, empagliflozin Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 1, 2024 Category: Research Source Type: clinical trials
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia
Conditions: Type 2 Diabetes Interventions: Drug: Empagliflozin 25 MG; Drug: Sitagliptin 100mg Sponsors: Medanta, The Medicity, India; Diabetes& Endocrinology Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 1, 2024 Category: Research Source Type: clinical trials
Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition
Conditions: Type2 Diabetes Mellitus Interventions: Drug: Empagliflozin film coated tablets; Drug: Jardiance film-coated tablets Sponsors: Humanis Sagl ık Anonim Sirketi Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials
EMPagliflozin After Aortic Valve Replacement
Conditions: Aortic Valve Stenosis Interventions: Drug: Empagliflozin; Drug: Placebo Sponsors: Rigshospitalet, Denmark Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of SGLT2 Inhibitor Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study
Conditions: Cystic Fibrosis-related Diabetes; Cystic Fibrosis Interventions: Drug: Empagliflozin; Other: Placebo Control Sponsors: Amir Moheet Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
Conditions: Glucose Metabolism Disorders; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Empagliflozin Interventions: Drug: Empagliflozin 10 MG; Drug: Insulin+Metformin+DPP4 inhibitor (DPP4I) Sponsors: SINA Health Education and Welfare Trust; Horizon Pharmaceutical Pvt Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 24, 2023 Category: Research Source Type: clinical trials
Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome.
Conditions: Polycystic Ovary Syndrome; Weight Gain; HbA1c Interventions: Drug: Empagliflozin 10 MG; Drug: MetFORMIN 500 Mg Oral Tablet Sponsors: SINA Health Education and Welfare Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
Conditions: Post-operative Atrial Fibrillation; CABG Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Sponsors: Rajaie Cardiovascular Medical and Research Center; Tehran Heart Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Role of Empagliflozin in Kidney Dysfunction and Podocyte Specific Injury in African American Veterans With Non-Diabetic Chronic Kidney Disease (CKD)
Conditions: Chronic Kidney Diseases Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Sponsors: Washington D.C. Veterans Affairs Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
Conditions: Cancer Interventions: Drug: Empagliflozin 10 MG Sponsors: Ain Shams University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus
Conditions: Diabetes Mellitus; Kidney Transplant; Complications Interventions: Drug: Empagliflozin 25 MG; Drug: Linagliptin 5 mg Oral Tablet Sponsors: Medanta, The Medicity, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
